Regional healthy brain activity, glioma occurrence and symptomatology

Supplementary Materials

Spin test results

Supplementary Table 1. Associations between regional glioma occurence and regional intrinsic brain activity using the spin test

Subgroup	Cohort	N	Broadband power	Offset	Slope
IDH-mutant, non-codeleted	AMS	30	NA	0.396 (0.023)*	NA
	MGH	18	NA	0.305 (0.137)	NA
	combined	*48*	*NA*	*0.407 (0.029)**	*NA*
IDH-wildtype glioma	AMS	14	NA	0.418 (0.051)	NA
	MGH	91	0.278 (0.006)*	0.315 (0.034)*	-0.437 (0.005)*
	TCGA	102	0.270 (0.003)*	0.309 (0.040)*	-0.387 (0.002)*
	combined	*207*	*0.307 (0.004)**	*0.429 (0.015)**	-0.446 (0.010)*

Cells indicate Spearman correlation (P-value). * $P < 0.05$ (note that correlation coefficients are the original correlations as indicated in Table 2. AMS = Amsterdam, MGH = Boston, TCGA = The Cancer Genome Atlas. Values indicate Spearman correlation coefficients.

Impact of medial regions

As evident from Supplementary Figure 1 on the next page, medial regions tended to have higher brain activity values in healthy controls. Since areas further away from the MEG sensors are known to have lower signal-to-noise (SNR) ratios than regions on the cortical surface,[1] we cannot fully exclude the potential confounding effect of SNR on brain activity values from those regions. Furthermore, since glioma also often occurs more medially, in the white matter, than on the cortical surface, where the MEG signal originates,[2] we used only the regions with brain activity values below the top quartile (i.e. regions with values lower than the 75th percentile) for our main analysis. When taking all regions into account, however, all significant main results are replicated (Supplementary Table 2).

Supplementary table 2. Associations between regional glioma occurrence and regional intrinsic brain activity when taking all regions into account

Subgroup	**Cohort**	**N**	**Broadband power**	**Offset**	**Slope**
IDH-mutant, 1p/19q-codeleted glioma	*AMS*	*21*	*-0.059*	*-0.010*	*0.239**
IDH-mutant, non-codeleted glioma	AMS	30	0.188	0.433*	-0.258*
	MGH	18	0.051	0.267*	-0.002
	combined	*48*	*0.177*	*0.424**	*-0.208**
IDH-wildtype glioma	AMS	14	0.057	0.282*	-0.211
	MGH	91	0.272*	0.335*	-0.373*
	TCGA	102	0.243*	0.287*	-0.440*
	combined	*207*	*0.233**	*0.358**	*-0.460**

* $P < 0.0019$, significant after correction for multiple comparisons across 27 tests. AMS = Amsterdam, MGH = Boston, TCGA = The Cancer Genome Atlas. Values indicate Spearman correlation coefficients.

Supplementary Figure 1. Average regional brain activity and variability in healthy controls



Legend. (A) depicts the spatial distribution of average broadband power plotted on the brain for the left and right lateral and medial hemispheres, in addition to the variability of regional broadband power values, indicated by gray error bars that represent standard deviation over the 45 healthy controls included in the analysis. Black dots are the non-medial regions, red dots are

the medial regions that are subject to lower signal-to-noise ratio and were excluded from our primary analyses. (B) displays the same for offset, and (C) for slope.

Supplementary Figure 2. Tumor occurrence maps per cohort



Legend. Tumor occurrence maps for (A) the Amsterdam (AMS) cohort, (B) the Massachusetts General Hospital (MGH) cohort, and (C) The Cancer Genome Atlas (TCGA) cohort.

Impact of age of healthy controls

The included healthy controls were matched to the primary AMS cohort and were significantly younger than patients in the MGH cohort ($t(152) = 5.035$, $P < 0.001$). Because of this age difference, additional analyses were performed to assure that any findings specifically in the MGH/TCGA cohorts and the IDH-wildtype gliomas were not due to this age difference. We calculated average regional brain activity values for the youngest healthy controls (age < 45

years, n = 21) and the oldest healthy controls (age > 45 years, n = 44) separately, to explore the potential confounding effects of this age difference on our analyses.

Results show that the distribution of regional brain activity was nearly identical between these two healthy control groups (broadband power Spearman's rho = 0.973, $P < 0.001$; offset Spearman's rho = 0.983, $P < 0.001$; Spearman's slope rho = 0.965, $P < 0.001$). We therefore decided to generally use the same 45 healthy controls for all analyses, to avoid comparisons with different control groups for each subgroup. However, for specific analyses within the older IDH-wildtype glioblastoma patients, we replicated our main findings using only the better matched, older healthy controls (data not shown).

Regional versus individual variability

Since we used the average of regional intrinsic activity values over all controls as either a correlate of tumor occurrence or to construct signatures of activity according to individual patients' tumor locations, we further explored the spatial distribution and variation around the mean of the three brain activity values (see Supplementary Figure 1). These figures suggest that there are meaningful differences between brain regions with respect to intrinsic activity values. Particularly for offset and slope, there are variations in the average values along the anterior-posterior axis that exceed the variability over controls, also in those non-medial regions we included in our main analyses. For broadband power, there are less consistent patterns to be seen, although the effect of lower SNR in the medial regions (also indicated by the greater variability for those red dots) may have obscured some variations in the non-medial areas.

Supplementary table 3. Differences in brain activity between patients with low and high KPS

	AMS cohort			
Brain activity measure	**KPS < 90 (n=23)**	**KPS 90 or 100 (n=38)**	**test statistic**	**p-value**
LENS-bbp	33034 (28378-37306)	31392 (24616-38882)	U = 371	0.326
LENS-offset	7.17 (7.06-7.25)	7.15 (7.02-7.26)	U = 387	0.457
LENS-slope	1.11 (1.08-1.13)	1.08 (1.05-1.13)	U = 299	0.040*
Subgroup (LENS-slope only)	**KPS < 90**	**KPS 90 or 100**	**test statistic**	**p-value**
IDH-mutant, 1p/19q-codeleted	n=7; 1.08 (1.08-1.11)	n=10; 1.06 (1.04-1.09)	U = 16	0.064
IDH-mutant, non-codeleted	n=5; 1.13 (1.12-1.14)	n=18; 1.07 (1.05-1.13)	U = 22	0.086
IDH-wildtype	n=5; 1.13 (1.12-1.16)	n=3; 1.10 (1.08-1.10)	U = 1	0.053

	MGH cohort			
Brain activity measure	**KPS < 90 (n=29)**	**KPS 90 or 100 (n=66)**	**test statistic**	**p-value**
LENS-bbp	31983 (27344-36872)	30907 (25320-40533)	U = 884	0.555
LENS-offset	7.15 (7.06-7.22)	7.13 (7.02-7.23)	U = 843	0.357
LENS-slope	1.12 (1.08-1.14)	1.10 (1.07-1.14)	U = 852	0.396

* $P < 0.05$. Cells indicate median (Q1-Q3), and subgroup sample size where necessary. KPS = Karnofsky Performance Scale

Supplementary Table 4. Associations between LENS and tumor volume per subgroup and cohort, adjusted for tumor lateralization

(Sub)group	**Cohort**	**n**	**Broadband power**	**Offset**	**Slope**
Subgroup 1 (IDH-mutant, 1p/19q-codeleted)	AMS	21	0.256	0.299	-0.339
Subgroup 2 (IDH-mutant, non-codeleted)	AMS	30	0.371*	0.458*	-0.478**
	MGH	18	-0.275	-0.149	0.033
Subgroup 3 (IDH-wildtype)	AMS	14	-0.088	0.010	0.285
	MGH	91	0.078	0.117	0.047

* $P < 0.05$, ** $P < 0.01$. AMS = Amsterdam, MGH = Boston. Values indicate standardized betas.

Supplementary table 5. Differences in LENS values between patients with and without epilepsy

	AMS cohort			
Brain measure	**Epilepsy (n=60)**	**No epilepsy (n=11)**	**test statistic**	**p-value**
LENS-bbp	31675 (25750-37783)	29692 (22262-35330)	U = 388	0.357
LENS-offset	7.16 (7.02-7.25)	7.13 (7.03-7.15)	U = 391	0.332
LENS-slope	-1.11 (-1.06--1.13)	-1.08 (1.06--1.13)	U = 402	0.253

	MGH cohort			
Brain measure	**Epilepsy (n=69)**	**No epilepsy (n=22)**	**test statistic**	**P-value**
LENS-bbp	31341 (25388-38801)	56335 (26367-64838)	U = 544	0.046*
LENS-offset	7.12 (7.03-7.22)	7.18 (7.04-7.39)	U = 563	0.069
LENS-slope	-1.12 (-1.07--1.14)	-1.12 (-1.08--1.15)	U = 690	0.522
LENS-bbp only	**Epilepsy**	**No epilepsy**	**test statistic**	**P-value**
IDH-mutant, non-codeleted	n=12; 26368 (23037-40426)	n=5; 37030 (29940-75994)	U = 9	0.027*
IDH-wildtype	n=57; 32506 (25690-41788)	n=17; 35640 (26079-59489)	U = 398	0.266

* $p < 0.05$. Cells indicate median (Q1-Q3), and subgroup sample size where appropriate.

Supplementary table 6. Associations between LENS values and survival

	AMS cohort			
IDH-mutant, 1p/19q-codeleted	**PFS**	**p-value**	**OS**	**p-value**
LENS-bbp	1.00 (1.00-1.00)	0.947	1.00 (1.00-1.00)	0.639
LENS-offset	0.31 (0.01-74.58)	0.676	11.26 (0.01-2.77*10^5)	0.639
LENS-slope	0.47 (0.01-2.10*10^7)	0.933	4.55 (0.01-2.16*10^{15})	0.930
IDH-mutant, non-codeleted	**PFS**	**p-value**	**OS**	**p-value**
LENS-bbp	1.00 (1.00-1.00)	0.742	1.00 (1.00-1.00)	0.879
LENS-offset	1.45 (0.06-35.56)	0.821	1.94 (0.01-276.10)	0.793
LENS-slope	0.319 (0.01-92.43*10^2)	0.827	95.08 (0.01-6.20*10^9)	0.620
IDH-wildtype	**PFS**	**p-value**	**OS**	**p-value**
LENS-bbp	1.00 (1.00-1.00)	0.430	1.00 (1.00-1.00)	0.363
LENS-offset	5.81 (0.07-478.16)	0.434	529 (0.04-642.65)	0.496
LENS-slope	1373.42 (0.01-9.30*10^{10})	0.432	8.40 (0.01-2.01*10^9)	0.829
	MGH cohort			
IDH-mutant, non-codeleted	**PFS**	**p-value**	**NA**	**NA**
LENS-bbp	1.00 (1.00-1.00)	0.467		
LENS-offset	16.28 (0.02-16453.74)	0.429		
LENS-slope	245.63 (0.01-1.24*10^{11})	0.590		
IDH-wildtype	**PFS**	**p-value**	**OS**	**p-value**
LENS-bbp	1.00 (1.00-1.00)	0.071	1.00 (1.00-1.00)	0.861
LENS-offset	3.35 (0.79-14.15)	0.100	0.91 (0.19-4.26)	0.902
LENS-slope	28.84 (0.05-16.47*10^3)	0.299	1.67 (0.01-830.06)	0.871

Cells indicate HR (95% confidence interval). PFS = progression-free survival, OS = overall survival. Note that none of the MGH IDH-mutant, non-codeleted patients died within follow-up.

References

1. Goldenholz DM, Ahlfors SP, Hamalainen MS, et al. Mapping the signal-to-noise-ratios of cortical sources in magnetoencephalography and electroencephalography. *Hum Brain Mapp*. 2009;30(4):1077-1086.

2. Hari R, Puce A. *MEG-EEG Primer*. Oxford University Press; 2017.